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Abstract
Background: Osteoporosis is a well-known complication of ankylosing spondylitis (AS). However, data about body
composition modifications and muscle performance showed conflicting results. The aim of the study was to determine
the prevalence and risk factors of pre-sarcopenia, sarcopenia and cachexia in patients with AS and analyze its relationship
with bone loss and symptomatic and severity parameters of the disease.
Methods: Sixty-seven consecutive male patients with AS (mean age of 40.9 ± 11.0 years) and 67 healthy controls were
studied. Body composition and bone mineral density (BMD) scans were obtained using DXA. The fat-free mass index
(FFMI; fat-free mass divided by height squared) and the percent of fat mass (%FM) were calculated. Pre-sarcopenia was
defined by low skeletal muscle mass (SMI <7.25 kg/m2), sarcopenia by the combined presence of the two following
criteria: SMI <7.25 kg/m2 and a low muscle strength (handgrip strength <30 kg) or a low muscle performance (timed
get-up-and-go test >10 s) and cachexia by a BMI <20 kg/m2 plus 3 from the 5 following parameters: anorexia, fatigue,
handgrip strength <30 kg, CRP >5 mg/l, SMI <7.25 kg/m2.
Results: Pre-sarcopenia, sarcopenia, cachexia, and osteoporosis prevalences were (50.4, 34.3, 11.9, and 16.0) respectively.
Patients had a mean 3 kg significant decrease in FFM and a 1 kg/m2 decrease in appendicular mass vs. healthy controls.
Pre-sarcopenia, sarcopenia and cachexia were significantly associated to higher BASDAI levels and low BMD.
Conclusion: Our study showed that men with AS had a statistically significant reduction in total and appendicular lean
mass that is related to higher disease activity and significantly associated to bone loss.
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Background
Sarcopenia is a term that was used first to define age re-
lated skeletal muscle wasting. Now, it is used to describe
all kinds of loss of muscle tissue and function whatever the
cause is (aging, chronic diseases, or low protein-energy in-
take and physical inactivity) [1]. In the context of chronic
inflammatory disorders, some authors called cachexia the
accelerated loss of skeletal muscle to differentiate it from
the age related sarcopenia. However, the spectrum of body
composition changes in disease states varies widely from a
minimal weight loss related to skeletal muscle wasting to
an extreme state of loss of fat and muscle in refractory
cachexia (as in cancer), including the particular case of the
normal or high BMI of sarcopenic obesity, that combines
high muscle loss with increased fat mass (as reported in
rheumatoid arthritis) [2]. Sarcopenia, as defined by muscle
loss and dysfunction, is a common feature of all chronic in-
flammatory diseases and involves impairment of either
contractile, metabolic and endocrine functions of skeletal
muscle [3] and is related to elevated circulating proinflam-
matory cytokines and especially tumor necrosis factor
(TNF). As also patients with ankylosing spondylitis (AS)
show elevated levels of these cytokines [4], sarcopenia
would be expected in this population.
Sarcopenia diagnosis relies currently on determination
of muscle mass, strength and physical performance.
Assessment of muscle mass can be done using several
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techniques such as anthropometry, bioimpedance analysis
(BIA), dual energy X-ray absorptiometry (DXA), computed
tomography (CT) scan and magnetic resonance imaging
(MRI). Although CT and MRI are considered as gold stan-
dards for estimating muscle mass in research, DXA is the
preferred alternative method for research and clinical use
for body composition assessment [5]. Muscle strength can
be measured reliably using the handheld dynamometer
in upper extremities while physical performance can be
assessed using several tests such as the gait speed, the
Timed Get-Up-and-Go and the Short Physical Perform-
ance Battery. The latter includes standing balance, gait
speed, and chair rises (sit-to-stand). It is noteworthy
however to remind that no specific definition of sarcope-
nia in inflammatory chronic disease populations exists.
Many studies of body composition in patients with AS
are published and did not consistently shown a reduc-
tion in muscle mass [6–8]. These conflicting findings
may be related to the differences in the studied populations
(such as disease duration and severity) and the variety of
methods used to assess body composition. In the other
hand, it is well established that osteoporosis, even in the
early stages of AS, is a common feature that seems to be
related to disease severity [9–11].
Therefore, the aim of this study was to determine the
prevalence and risk factors of pre—sarcopenia/sarcope-
nia/cachexia in a group of patients with AS and analyze
its relationship with osteoporosis and symptomatic and
severity parameters of the disease.
Methods
Patients and healthy controls
The study group consisted in 67 male patients with AS
who fulfilled the modified New York criteria for the clas-
sification of AS and who presented consecutively to our
department between September 2014 and July 2015. A
group of 67 age-matched (within 2 yrs) healthy subjects
was recruited from the same local population (hospital
staff members and their family members, visitors…etc.)
to serve as controls according to exclusion criteria. A
subjects’ written consent was obtained according to the
Declaration of Helsinki and the study was approved by
our local ethics committee (Military Hospital Mohammed
V, Rabat). Exclusion criteria were the presence of a history
of neuroendocrine disorders (thyroid, parathyroid dis-
orders, anticonvulsant usage etc.), chronic renal or liver
diseases, systemic high dose steroid use, and excessive
alcohol intake. The following data were collected for all
the subjects: age, height, weight, and body mass index
(BMI). The time elapsed between the onset of first AS
related symptoms and enrollment defined disease dur-
ation. Disease activity and the functional consequences
of the disease were assessed by the Bath AS disease ac-
tivity index (BASDAI) and the Bath AS functional index
(BASFI), respectively. Erythrocyte sedimentation rate
(ESR) and C-reactive protein (CRP) were assessed using
standard laboratory techniques. Sacroiliitis was assessed
on anteroposterior pelvic radiographs and graded accord-
ing to the New York Scale. Spine structural damage was
assessed by the Stoke AS Spinal Score (SASSS) in which
each corner is scored for the presence of squaring,
sclerosis, erosions, syndesmophytes and bridging syn-
desmophytes with a maximal score of 72.
Bone mineral density measurements
The DXA scans were obtained by standard procedures
using Lunar Prodigy Vision machine. All BMD measure-
ments were carried out by 2 experienced technicians.
Daily quality control was carried out by measurement of
a Lunar phantom which showed at the time of the study
stable results. The coefficient of variation of the phantom
precision was 0.08 and the reproducibility assessment in
clinical practice showed in a previous study a smallest de-
tectable difference of 0.04 g/cm2 (spine) and 0.02 (hips)
[12]. Patient BMD was measured at the lumbar spine
(anteroposterior projection at L1–L4) and at the femurs
(i.e., femoral neck, trochanter, and total hips) and the classi-
fication system of the World Health Organization (WHO)
was applied, defining osteoporosis as T-score ≤ −2.5 and
osteopenia as −2.5 < T-score ≤ −1 according to the lowest
T-score of the L1–4 lumbar spine, femur neck, or total
femur.
Body composition parameters assessment
All anthropometric measures were taken following
standard procedures by the same investigator (FBE). The
subjects were weighed to the nearest 0.1 kg, and standing
height was measured to the nearest 0.1 cm and BMI was
then calculated from weight/height2 (kg/m2). In ac-
cordance with WHO standards, individuals with BMI
values <18.5 kg/m2 were considered underweight, between
18.5 and 24.9 as normal, 25 and 29.9 as overweight and
values greater than 30 indicated obesity [13]. Mid upper
arm circumference and waist circumference were mea-
sured using a plastic, inelastic, flexible belt-type measuring
tape to the nearest 0.5 cm.
Body composition (total and regional fat mass and
lean mass) was measured with total body DXA using
the same machine. The whole body scan used the
DXA system’s automated software, which provided
compositional estimates of legs, arms, trunk, head,
and whole body. Scans were performed with the sub-
ject wearing light indoor clothing. The precision of
soft tissue analysis for a Lunar Prodigy is 1 % for fat-
free mass (FFM) and 2 % for fat mass (FM) [14].
FFM and FM were expressed in absolute kg, and FM
also as percentage of total mass. The normal refer-
ence value for FM% is 20 % to 30 % for women and
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12 % to 20 % for men [15]. Fat free mass index
(FFMI, kg/m2), fat mass index (FMI, kg/m2) and skel-
etal mass index (SMI, kg/m2, where appendicular
skeletal muscle mass is standardized using the square
of the individuals’ height) were also calculated.
Muscle strength and performance assessment
Maximal voluntary grip strength of the dominant hand
was measured with a Grip-A dynamometer (Takey, Kiki
Kogyo, Japan). This assessment could be easily done as
only 4 patients among the study population had peripheral
involvement and none of the patients had hand joints
involvement.
Global muscle performance was assessed by the Timed
Get-Up-And-Go test: the subject rises from a chair,
walks 3 meters, turns around, returns to the chair, and
sits down. The subject was instructed to: “Sit with your
back against the chair and your arms on the arm rests.
On the word ‘go’, stand upright, then walk at your nor-
mal pace to the line on the floor, turn around, return to
the chair, and sit down.“ The stopwatch was started on
the word ‘go’ and stopped when the subject returned to
the starting position.
Mini Nutritional Assessment
The MNA (0–30 points) is a dietary questionnaire asses-
sing the number of meals, food and fluid intake and
autonomy of feeding. It is a subjective assessment of
self-perception of health and nutrition which also includes
questions related to lifestyle, medication and morbidity.
MNA classifies individuals with adequate nutritional
status (>23.5 points), with risk for malnutrition (17–23.5
points) and with malnutrition (<17 points) [16].
Definition of pre-sarcopenia, sarcopenia and cachexia
As a consequence of the lack of a simple and commonly
accepted definition for these conditions, we choose arbi-
trarily one from the published definitions:
 Pre-sarcopenia was defined according to
Baumgartner definition [17] by SMI <7.25 kg/m2.
 Sarcopenia was defined by the combined presence of
the two following criteria according to the European
Working Group on Sarcopenia in Older People
(EWGSOP) [5]: a low muscle mass (SMI <7.25 kg/m2)
and a low muscle strength (assessed by a handgrip
strength <30 kg) or a low muscle performance
(assessed by a timed get-up-and-go test >10 s).
 Cachexia was defined according to the
International Working Group on Sarcopenia
(IWGS) definition [18] by a BMI <20 kg/m [2]
plus 3 from the 5 following parameters: anorexia,
fatigue, handgrip strength <30 kg, CRP >5 mg/l,
FFMI <7.25 kg/m2.
Statistical analysis
The study was conducted on several steps. Step one con-
sisted on the description of the study population. We
compared in step 2 anthropometric and densitometric
(BMD and body composition) variables between patients
and healthy controls. In step 3, 4 and 5, we compared
patients with or without pre-sarcopenia, sarcopenia and
cachexia. A regression binary analysis was conducted in
step 6 where the dependant variable was the presence of
pre-sarcopenia and the independent variables the poten-
tial risk factors. And finally, to study the potential im-
pact of TNF inhibitors (TNFi), in step 7, we compared
patients taking or not TNFi.
Statistics Package for Social Sciences (SPSS Inc.,
Chicago, IL) was used for statistical analyses. Results
are expressed in mean ± SD for quantitative variables
and n (%) for qualitative variables.
Results
Subject characteristics
Subject characteristics are shown in Table 1. The mean ±
SD (range) for age, disease duration and BASDAI score
were 40.9 ± 11.0 years (18–66), 9.3 ± 7.9 years (1–36) and
3.7 (range 0–8.6) respectively. The proportion of patients
with “active disease” according to the BASDAI (score of ≥4)
was 32 (47.8 %). Twenty two (32.8 %) patients used TNFi
since a mean duration of 2.3 years (range 0.25 – 7).
Patients vs. healthy controls
Table 2 shows all of the body composition data for the
patients and controls. Patients had a mean 3 kg signifi-
cant decrease in FFMI and a 1 kg/m2 decrease in SMI.
There was also a significant difference in lumbar spine
Table 1 Demographic characteristics and clinical features
(symptomatic and structural disease severity parameters) in our
study population with AS
Minimum Maximum
Age (yrs): m (SD) 40.7 (11.0) 18 66
Disease duration (yrs): m (SD) 9.3 (7.9) 1 36
BASDAI: m (SD) 3.7 (2.4) 0 8.6
BASMI: m (SD) 2.8 (5.5) 0 36
BASFI: m (SD) 40.5 (28.1) 0 83
BAS-G: m (SD) 17.5 (22.7) 0 72
ESR (mm/H): m (SD) 27.1 (21.0) 2 78
CRP (mg/l) : m (SD) 15.3 (25.1) 0.3 168.0
SASSS: m (SD) 10.7 (15.7) 0 72
Anti-TNF use : n (%) 22 (32.9)
Anti-TNF use duration (yrs): m (SD) 2.3 (1.7) 0.25 7
CRP C-reactive protein, ESR erythrocyte sedimentation rate, SASSS Stoke Ankylosing
Spondylitis Spinal Score
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and total hip bone mass and T-scores. Whereas there
was 16 % among the patients that has osteoporosis
(T-score below −2.5 in either the lumbar spine or the
total hip) and 50.7 % that has pre-sarcopenia according to
the definition of Baumgartner (low skeletal muscle mass:
SMI <7.25 kg/m2), only 3 % of the controls had osteopor-
osis and 28 % had pre-sarcopenia. None of our patients
had history of clinical fractures. Moreover, Vertebral frac-
tures were assessed using VFA in 33 patients among the
study population and showed mild fractures in only 3 pa-
tients (data not shown).
Determinants of pre-sarcopenia, sarcopenia and cachexia
Tables 3, 4, and 5 show the comparison between patients
with and without pre-sarcopenia, with and without sar-
copenia and with and without cachexia respectively.
Globally, they showed that higher BASDAI levels, lower
lumbar spine and hip BMD and T-scores and higher
prevalence of osteoporosis are significantly associated
to pre-sarcopenia, sarcopenia and cachexia.
Table 6 shows regression binary analysis where pre-
sarcopenia as defined by Baumgartner (SMI <7.25 kg/m2)
was the dependent variable: BASDAI was the only variable
significantly associated to pre-sarcopenia.
Impact of TNFi treatment
Comparison between patients taking or not TNFi (Table 7)
showed that patients taking TNFi had a statistically sig-
nificant longer disease duration and higher FMI and
lumbar spine BMD and T-scores. No difference was ob-
served in muscle mass, muscle strength or performance
tests or symptomatic or structural severity parameters
of AS.
Table 3 Comparison of anthropometric, clinical and
densitometric variables between patients with AS with and








Age (yrs): m (SD) 42.1 (11.6) 40.7 (10.7) NS
Height (m): m (SD) 1.71 (0.06) 1.73 (0.06) NS
Weight (kg): m (SD) 64.6 (11.0) 76.9 (11.9) <0.0001
BMI (kg/m2): m (SD) 21.6 (3.6) 25.7 (3.7) <0.0001
Disease duration (yrs):
m (SD)
9.4 (9.1) 9.1 (6.6) NS
Lumbar spine BMD
(g/cm2): m (SD)
1.077 (0.23) 1.164 (0.14) NS
Lumbar spine T-score:
m (SD)
−1.05 (3.4) −0.22 (1.2) 0.032
Total hip BMD (g/cm2):
m (SD)
0.925 (0.13) 1.026 (0.23) 0.017
Total hip T-score:
m (SD)
−0.89 (1.4) −0.22 (1.1) 0.017
Osteoporosis: n (%) 10 (30.3) 3 (8.8) 0.0033
BASDAI (0–10): m (SD) 4.4 (2.4) 3.3 (2.5) 0.003
BASMI (0–10): m (SD) 2.8 (2.2) 2.8 (2.7) NS
BASFI (0–100): m (SD) 45.5 (26.5) 35.0 (25.5) NS
BAS-G (0–100): m (SD) 15.7 (16.8) 19.1 (22.6) NS
Hand grip strength (kg):
m (SD)
22.5 (7.0) 24.3 (9.8) NS
Timed get-up-and-go
test (sec) < 10 sec: n (%)
23 (74.2) 24 (75.0) NS
Arm circumference
(cm): m (SD)
26.8 (1.9) 30.5 (3.9) <0.0001
Waist circumference
(cm): m (SD)
85.7 (10.8) 97.1 (11.4) <0.0001
MNA test (0–17):
m (SD)
0.29 (0.4) 0.20 (0.3) NS
SASSS (0–72): m (SD) 11.8 (16.7) 10.0 (15.6) NS
CRP (mg/l): m (SD) 20.1 (10.1) 10.6 (10.1) NS
ESR (mm/H): m (SD) 33.0 (22.3) 21.2 (18.4) NS
Patients taking TNFi:
n (%)
13 (28.9) 9 (42.9) NS
BMI body mass index, CRP C-reactive protein, ESR erythrocyte sedimentation
rate, MNA Mini Nutritional Assessment, SASSS Stoke Ankylosing Spondylitis
Spinal Score
Table 2 Comparison of clinical variables, bone and body







Age (yrs): m (SD) 40.7 (11.0) 40.9 (11.0) NS
Height (m): m (SD) 1.72 (0.08) 1.74 (0.08) NS
Weight (kg): m (SD) 72.4 (13.2) 77.0 (12.0) NS
BMI (kg/m2): m (SD) 25.3 (4.0) 24.1 (3.4) NS
Fat-free mass (kg): m (SD) 49.2 (6.3) 52.0 (6.3) 0.014
Fat-free mass index (kg/m2):
m (SD)
16.3 (2.0) 17.2 (1.9) 0.007
Fat mass (kg): m (SD) 21.2 (10.5) 22.8 (9.7) NS
Fat mass index (kg/m2): m (SD) 6.9 (3.1) 7.5 (3.7) NS
Appendicular mass (kg): m (SD) 22.2 (3.0) 23.4 (3.3) 0.033
Appendicular mass index
(kg/m2): m (SD)
7.4 (0.8) 7.7 (0.9) NS
Lumbar spine BMD (g/cm2):
m (SD)
1.19 (0.1) 1.12 (0.1) 0.023
Lumbar spine T-score: m (SD) −0.64 (2.5) −0.10 (2.5) 0.019
Total hip BMD (g/cm2): m (SD) 0.97 (0.1) 1.08 (0.1) <0.0001
Total hip T-score: m (SD) −0.56 (1.3) 0.42 (1.1) <0.0001
Osteoporosis any site: n (%) 13 (19.4 %) 2 (3.0) 0.002
Pre-sarcopenia: n (%) 33 (49.3) 19 (28.4) <0.01
BMI body mass index, SASSS Stoke Ankylosing Spondylitis Spinal Score
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Discussion
This study showed that men with AS had statistically
significant reduction in total (3 kgs) and appendicular
lean mass. These results are concordant with those of
some previous DXA studies on the effects of AS on body
composition: one study found a statistically non-significant
reduction of 3 kg of total lean mass [6, 19] and the other
study found a higher statistically significant difference
of 6 kgs [20]. This lean mass loss seems to be related to
higher disease activity and inflammation and signifi-
cantly associated to bone loss.
As early as in the third century B.C., Hippocrates de-
scribed the wasting syndrome associated to chronic
diseases. Indeed, several metabolic abnormalities sec-
ondary to chronic diseases of multifactorial origin are
observed. The term sarcopenia, which is derived from
the Greek words sarx (flesh) and penia (poverty), describes
Table 4 Comparison of anthropometric, clinical and
densitometric variables between patients with AS with and








Age (yrs): m (SD) 42.3 (11.6) 40.1 (10.7) NS
Height (m): m (SD) 1.71 (0.06) 1.73 (0.06) NS
Weight (kg): m (SD) 64.6 (11.0) 77.9 (11.9) <0.0001
BMI (kg/m2): m (SD) 21.6 (3.6) 25.7 (3.7) <0.0001
Disease duration (yrs):
m (SD)
11.6 (9.1) 8.6 (6.6) NS
Lumbar spine BMD
(g/cm2): m (SD)
1.092 (0.23) 1.134 (0.14) NS
Lumbar spine T-score:
m (SD)
−0.97 (3.4) −0.47 (1.2) 0.032
Total hip BMD (g/cm2):
m (SD)
0.914 (0.13) 1.006 (0.23) 0.017
Total hipT-score: m (SD) −0.96 (1.4) −0.35 (1.1) 0.017
Osteoporosis: n (%) 7 (30.4) 4 (9.1) 0.038
BASDAI (0–10): m (SD) 4.4 (2.4) 3.4 (2.5) 0.002
BASMI (0–10): m (SD) 2.9 (2.2) 2.7 (2.7) NS
BASFI (0–100): m (SD) 44.5 (26.5) 38.0 (25.5) NS
BAS-G (0–100): m (SD) 19.7 (16.8) 16.1 (22.6) NS
Hand grip strength (kg):
m (SD)
19.5 (7.0) 25.3 (9.8) NS
Timed get-up-and-go
test (sec) < 10 sec: n (%)
14 (66.7) 33 (75.0) NS
Arm circumference
(cm): m (SD)
26.8 (1.9) 30.5 (3.9) 0.002
Waist circumference
(cm): m (SD)
85.7 (10.8) 94.1 (11.4) <0.0001
MNA test (0–17): m (SD) 0.34 (0.4) 0.19 (0.3) NS
SASSS (0–72): m (SD) 14.3 (18.7) 9.5 (14.6) NS
CRP (mg/l): m (SD) 21.8 (10.1) 11.6 (10.1) NS
ESR (mm/H): m (SD) 31.0 (22.3) 24.2 (18.4) NS
Patients taking TNFi:
n (%)
11 (33.3) 11 (32.4) NS
BMI body mass index, CRP C-reactive protein, ESR erythrocyte sedimentation
rate, MNA Mini Nutritional Assessment, SASSS Stoke Ankylosing Spondylitis
Spinal Score
Table 5 Comparison of anthropometric, clinical and
densitometric variables between patients with AS with and








Age (yrs): m (SD) 36.5 (13.6) 41.5 (10.7) NS
Height (m): m (SD) 1.73 (0.06) 1.72 (0.06) NS
Weight (kg): m (SD) 53.7 (11.0) 75.2 (11.9) <0.0001
BMI (kg/m2): m (SD) 21.6 (3.6) 26.7 (3.7) <0.0001
Disease duration (yrs):
m (SD)
8.3 (9.1) 9.4 (6.6) NS
LS BMD (g/cm2): m (SD) 1.150 (0.23) 0.892 (0.14) <0.0001
LS T-score: m (SD) −2.45 (3.4) −0.38 (1.2) <0.0001
TH BMD(g/cm2): m (SD) 0.856 (0.13) 0.991 (0.23) 0.037
TH T-score: m (SD) −1.45 (1.4) −0.44 (1.1) 0.016
Osteoporosis: n (%) 6 (75.0) 7 (11.9) <0.0001
BASDAI (0–10): m (SD) 5.4 (2.4) 3.5 (2.5) 0.007
BASMI (0–10): m (SD) 3.5 (2.2) 2.7 (2.7) NS
BASFI (0–100): m (SD) 52.3 (26.5) 35.0 (25.5) NS
BAS-G (0–100): m (SD) 29.5 (16.8) 15.9 (22.6) NS
Hand grip strength (kg):
m (SD)
19.1 (7.0) 23.8 (9.8) NS
Get-up and go test
(sec) < 10 sec: n (%)
6 (75.0) 41 (74.5) NS
Arm circumference (cm):
m (SD)
25.8 (1.9) 29.5 (3.9) <0.0001
Waist circumference (cm):
m (SD)
78.4 (10.8) 92.8 (11.4) <0.0001
MNA test (0–17): m (SD) 0.62 (0.4) 0.19 (0.3) 0.008
SASSS (0–72): m (SD) 8.3 (4.7) 10.6 (16.6) NS
CRP (mg/l): m (SD) 39.2 (10.1) 11.6 (10.1) 0.013
ESR (mm/H): m (SD) 44.1 (22.3) 24.3 (18.4) 0.031
Patients taking TNFi: n (%) 21 (35.6) 1 (12.5) NS
BMI body mass index, BMD bone mineral density, CRP C-reactive protein,
ESR erythrocyte sedimentation rate, LS lumbar spine, MNA Mini Nutritional
Assessment, SASSS Stoke Ankylosing Spondylitis Spinal Score, TH total hip
Table 6 Multiple regression analysis with pre-sarcopenia as
defined by Baumgartner as the dependant variable
Exp (B) 95 % CI p
Age 1.008 0.941 – 1.080 NS
Disease duration 1.036 0.958 – 1.121 NS
BASDAI 1.050 1.002 – 1.086 0.029
CRP 1.017 0.967 – 1.070 NS
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a condition characterized by loss of muscle mass and
muscle strength [1, 21]. Although sarcopenia is primarily
a disease of the elderly, it may develop secondarily to con-
ditions that can be seen in younger patients such as in-
flammatory diseases. As the muscle mass and muscle
strength in younger individuals is high before it is affected
by these disorders, muscle mass and muscle strength loss
secondary to such disorders is usually thought to be func-
tionally less relevant. Diagnosis of sarcopenia is based on
the combined presence of a low muscle mass and a low
muscle strength and/or performance. Cachexia, which is
derived from the Greek words kako`s (bad) and he Ïxis
(condition), has been defined as a syndrome of multifac-
torial origins characterized by severe body weight, fat and
muscle loss and increased protein catabolism due to
underlying disease(s). Cachexia is clinically relevant since
it increases patients’ morbidity and mortality [22, 23].
Among the contributory factors to the onset of cachexia
we can list anorexia and metabolic alterations, i.e. in-
creased inflammatory status, increased muscle proteolysis,
impaired carbohydrate, protein and lipid metabolism. In-
flammation does play a crucial role in its pathogenesis and
its presence allows for cachexia identification. Cachexia is
linked to the disease activity of the chronic inflammatory
diseases through the effects of proinflammatory cytokines
such as tumor necrosis factor-α (TNF-α), interleukin 1
(IL-1), and IL-6. TNF-α (formerly called cachectin), a piv-
otal cytokine in rheumatic diseases, plays an important
role in the development of cachexia. Skeletal muscle mass
loss is considered the most clinically relevant phenotypic
feature of cachexia, irrespective of the underlying causative
disease [24].
In patients with RA, several studies, although not all,
have shown evidence for a decreased FFM compared to
healthy controls [25–27] often associated with increased
FM and thus, with little or no weight loss, and a main-
tained body mass index. This combined condition has
been called “rheumatoid cachexia”. In patients with AS,
evidence is however limited: Toussirot et al. [6] did not
found any difference in FFM or FM, as measured with
DXA, between patients and controls. In the study of Sari
et al. [7], using BIA, no difference in FFM between pa-
tients and controls was noted, but a lower percentage of
FM was observed in male patients compared to healthy
controls. The first study to show a lower appendicular
and total lean mass (that was related to lower functional
strength) was reported by Marcora et al. [20] in a series
of male patients with AS. Another study conducted by
Plasqui et al. [8] found no difference in FFM, and also
not when corrected for height (FFMI) or expressed as a
percentage of total body mass. In this study, the FFMI
was even slightly higher in patients and interestingly; the
observed values of the FFMI correspond to those of a
large sample of healthy subjects.
Furthermore, most of previous studies have not re-
ported the effects of AS on regional body composition.
This is important since it has been shown that the ap-
pendicular lean mass (arms and legs) is a better proxy
measure of total body skeletal muscle mass than total lean
mass or FFM [28]. In addition, trunk lean mass could be
related to spine immobility rather than the metabolic con-
sequences of systemic inflammation. Moreover, it has
been shown that body composition assessment using
DXA including the trunk might be slightly affected by the
kyphosis of the spine [29].
Table 7 Comparison of anthropometric, clinical and









Age (yrs): m (SD) 39.5 (11.4) 43.7 (11.5) NS
Height (m): m (SD) 1.73 (0.06) 1.70 (0.06) NS
Weight (kg): m (SD) 70.6 (14.2) 76.7 (13.3) NS
BMI (kg/m2): m (SD) 23.3 (4.5) 25.7 (4.2) NS
Disease duration (yrs): m (SD) 6.8 (6.0) 14.1 (8.9) 0.0001
FFMI: m (SD) 16.3 (1.8) 16.2 (2.0) NS
FMI: m (SD) 5.9 (3.3) 9.0 (3.5) 0.001
Pre-sarcopenia as defined
by Baumgartner : n (%)
23 (51.1) 11 (50.0) NS
Sarcopenia as defined
by EWGSOP: n (%)
12 (27.3) 9 (40.9) NS
Cachexia as defined by IWSG :
n (%)
7 (15.6) 1 (4.5) NS
LS BMD (g/cm2): m (SD) 1.08 (0.19) 1.19 (0.19) 0.029
LS T-score: m (SD) −0.90 (1.6) −0.07 (1.3) 0.034
TH BMD(g/cm2): m (SD) 0.986 (0.18) 0.945 (0.13) NS
TH T-score: m (SD) −0.50(1.1) −0.70 (1.0) NS
Osteoporosis: n (%) 10 (22.2) 1 (4.5) NS
BASDAI: m (SD) 3.7 (2.3) 3.6 (2.8) NS
BASMI: m (SD) 2.7 (52.5) 3.0 (2.5) NS
BASFI: m (SD) 39.5 (29.8) 41.0 (28.8) NS
Hand grip strength (kg): m (SD) 23.1 (9.2) 23.1 (9.1) NS
Get-up and go test (sec): m (SD) 3.4 (0.5) 2.0 (0.5) NS
Arm circumference (cm): m (SD) 28.0 (3.3) 29.9 (3.8) NS
Waist circumference (cm): m (SD) 88.3 (12.2) 97.5 (10.7) 0.004
MNA test: m (SD) 0.33 (0.4) 0.09 (0.2) 0.015
SASSS: m (SD) 11.6 (18.8) 7.0 (5.2) NS
CRP (mg/l): m (SD) 17.0 (30.2) 11.3 (9.9) NS
ESR (mm/h): m (SD) 29.3 (23.1) 22.3 (15.1) NS
BMI body mass index, BMD: bone mineral density, CRP: C-reactive protein, ESR
erythrocyte sedimentation rate, LS lumbar spine, MNA Mini Nutritional Assessment,
SASSS Stoke Ankylosing Spondylitis Spinal Score, TH total hip
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We found that AS-related sarcopenia was associated
to low BMD in this cohort. We have already highlighted
the link between lean mass loss and osteoporosis in
patients with AS [30]. We showed that bone loss is
common in AS and may be observed in early disease
and that it is linked to persistent inflammation [31].
Many studies showed a positive impact of treatment
with TNF inhibitors on BMD in patients with AS [32, 33].
However, whether TNF inhibitors have an effect on muscle
loss is still controversial.
Anti-TNF-α therapy induces a significant and sus-
tained reduction in clinical disease activity and systemic
inflammation, and improves measures of disability in
AS. In theory, anti-TNF therapy is expected to be effective
to treat or prevent cachexia in patients with rheumatic
disorders. As expected, infusions of anti-TNF-α antibodies
in animal models have shown anticachectic effects [34].
Recently, Marcora et al. reported the first randomized
controlled trial of anti-TNF therapy for cachexia in RA,
but did not observe changes in weight and body compos-
ition induced by this treatment in this population [35].
Briot et al. have shown in a 2-year study of 106 patients
with Spondyloarthropathies receiving anti-TNF therapy
that a significant increase in weight of 2.2 kg occurred in
2 years (mostly due to a significant gain in FM) in parallel
with an increase in BMD (+5.8 % at the lumbar spine
and +2.26 % at the femur) [36]. This is concordant with
the data of our study where one third of our patients
were taking TNF inhibitors (mean: 2.3 years) and which
show that patients taking TNF inhibitors has a signifi-
cantly higher FM and FMI.
Our study has strengths and limitations. The assessment
of body composition and BMD was carefully conducted
using standard procedures of acquisition. The main limita-
tion lies in the chosen definitions of pre-sarcopenia, sarco-
penia and cachexia. However, as no consensual definitions
exist, we used definitions developed by groups interested
in sarcopenia/cachexia study and based on published cut-
offs. Another limitation is the lack of data about vitamin
D status which was not included in the study protocol.
Further longitudinal studies are warranted to better evalu-
ate the association between bone and muscle loss in AS
and the long term effect of TNF inhibitors.
Conclusions
Our study showed that men with AS had a statistically
significant reduction in total and appendicular lean mass
compared to healthy age-matched controls. This lean
mass loss seems to be related to higher disease activity
and significantly associated to bone loss. Patients with
AS with important weight loss should be assessed using
body composition analysis. TNF inhibitors may have a
role in reducing muscle wasting.
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